Law firm advises investors of Mereo BioPharma Group plc to take action

Bronstein, Gewirtz & Grossman, LLC is alerting investors in Mereo BioPharma Group plc of a class action lawsuit filed against the company and some of its officers. The lawsuit aims to recoup damages for alleged violations of federal securities laws on behalf of individuals and entities who bought or otherwise acquired Mereo securities between June 5, 2023, and December 26, 2025.

During the Class Period, the lawsuit claims that the Defendants provided investors with overwhelmingly positive statements while also circulating materially false and misleading information or hiding important adverse facts regarding the true status of the Phase 3 ORBIT and COSMIC programs. These programs failed to meet their primary endpoints of reducing the annualized clinical fracture rate compared to the control groups of placebo or bisphosphonate.

For individuals invested in Mereo, a class action suit has already been initiated. Those interested in reviewing the Complaint can access it on the firm’s website. If they have experienced losses with Mereo securities, they have until April 6, 2026, to request appointment as lead plaintiff. It is not necessary to be the lead plaintiff to share in any potential recovery.

Bronstein, Gewirtz & Grossman, LLC specializes in representing investors in class actions related to securities fraud and shareholder derivative lawsuits. The firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys’ fees if they achieve success in the case.

Investors who choose to work with Bronstein, Gewirtz & Grossman, LLC for the Mereo Securities Class Action can rest assured that they are partnering with a well-regarded national firm with a history of representing investors effectively in similar cases. The firm operates on a contingency fee basis, ensuring that investors are only responsible for fees if the case is successful.